This, in contrast to the questionable BCL2 specificity of venetoclax, argues in favor of this protein as a potential predictive biomarker, as immunohistochemical staining is simple, i.e., either scoring as negative or positive (membranous/cytoplasmic staining in ≥30 % of tumor cells). This evidence concerns the gene BCL2 and neoplasm.